Celldex Financial Statements From 2010 to 2025

CLDX Stock  USD 23.35  0.13  0.56%   
Celldex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Celldex Therapeutics' valuation are provided below:
Gross Profit
-176.9 M
Market Capitalization
1.6 B
Enterprise Value Revenue
116.4761
Revenue
7.6 M
Earnings Share
(2.70)
We have found one hundred twenty available fundamental signals for Celldex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Celldex Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.8 B in 2025. Enterprise Value is likely to rise to about 1.8 B in 2025

Celldex Therapeutics Total Revenue

7.65 Million

Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 5.8 M or Selling General Administrative of 36.6 M, as well as many indicators such as Price To Sales Ratio of 243, Dividend Yield of 0.0 or PTB Ratio of 3.58. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Celldex Stock
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Celldex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets832 M792.3 M328.8 M
Slightly volatile
Other Current Liabilities36.5 M34.8 M17.4 M
Slightly volatile
Total Current Liabilities41.5 M39.5 M22.3 M
Slightly volatile
Property Plant And Equipment Net5.7 M8.2 M7.1 M
Pretty Stable
Cash31.1 M28.4 M39.6 M
Pretty Stable
Non Current Assets Total31.5 M45.2 M56.3 M
Very volatile
Cash And Short Term Investments761.5 M725.3 M265 M
Slightly volatile
Common Stock Shares Outstanding67.6 M64.4 M22.8 M
Slightly volatile
Liabilities And Stockholders Equity832 M792.3 M328.8 M
Slightly volatile
Non Current Liabilities Total5.5 M5.8 M17.8 M
Pretty Stable
Other Current Assets22.2 M21.2 M5.9 M
Slightly volatile
Other Stockholder Equity2.4 B2.3 B1.1 B
Slightly volatile
Total Liabilities26.3 M45.3 M38.7 M
Very volatile
Property Plant And Equipment Gross33.3 M31.7 M15.3 M
Slightly volatile
Total Current Assets784.5 M747.2 M271.5 M
Slightly volatile
Net Receivables916.9 K700 K1.1 M
Slightly volatile
Non Currrent Assets Other10.2 M9.7 M1.9 M
Slightly volatile
Accounts Payable3.4 M3.3 M1.9 M
Slightly volatile
Short and Long Term Debt Total4.6 M3.8 MM
Slightly volatile
Short Term Debt2.7 M1.5 M3.6 M
Slightly volatile
Common Stock Total Equity65.1 K54 K64 K
Pretty Stable
Common Stock64.8 K66 K65.2 K
Pretty Stable
Intangible Assets34.1 M31.3 M43.6 M
Very volatile
Current Deferred Revenue10.3 M10.8 M11.1 M
Very volatile
Other Liabilities5.8 M6.1 M14.9 M
Very volatile
Other Assets88.9 K93.6 K459.5 K
Slightly volatile
Property Plant Equipment7.2 MMM
Pretty Stable
Short Term Investments731.8 M696.9 M227 M
Slightly volatile
Net Tangible Assets361.1 M343.9 M182.5 M
Slightly volatile
Long Term Debt Total5.9 M5.2 M6.1 M
Slightly volatile
Capital SurpluseB1.8 BB
Slightly volatile
Non Current Liabilities Other3.3 M3.5 M16.5 M
Pretty Stable
Short and Long Term DebtM5.2 M4.1 M
Slightly volatile
Net Invested Capital784.4 M747 M314 M
Slightly volatile
Long Term Investments1.4 M1.6 M1.8 M
Slightly volatile
Net Working Capital743 M707.7 M237.9 M
Slightly volatile
Capital Stock44.8 K66 K26.6 K
Slightly volatile
Capital Lease Obligations2.7 M3.8 M3.5 M
Slightly volatile

Celldex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM3.2 M2.5 M
Slightly volatile
Selling General Administrative36.6 M38.5 M22.1 M
Slightly volatile
Total Revenue7.6 MM6.4 M
Very volatile
Other Operating Expenses212.2 M202.1 M105.8 M
Slightly volatile
Total Operating Expenses212.2 M202.1 M104.4 M
Slightly volatile
Research Development171.7 M163.6 M81.2 M
Slightly volatile
Selling And Marketing Expenses11 B16.9 B14.1 B
Slightly volatile
Non Recurring3.8 MM14.4 M
Very volatile
Non Operating Income Net Other551.7 K580.8 K1.9 M
Very volatile
Interest Income4.3 M4.8 M3.6 M
Slightly volatile
Reconciled DepreciationM3.2 M4.4 M
Slightly volatile
Extraordinary Items15.3 M17.2 M18.7 M
Slightly volatile

Celldex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow32.3 M28.4 M40.3 M
Pretty Stable
Begin Period Cash Flow31.4 M34.8 M39.8 M
Very volatile
Total Cash From Financing Activities463.5 M441.4 M142.4 M
Slightly volatile
Stock Based Compensation32.5 M34.2 M19 M
Pretty Stable
Change To Netincome15.7 M11 M13.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio243232238
Pretty Stable
Days Sales Outstanding43.2636.39659.9252
Slightly volatile
Average Payables1.5 M2.6 M2.7 M
Very volatile
Stock Based Compensation To Revenue4.634.87783.6267
Pretty Stable
EV To Sales240228230
Pretty Stable
Payables Turnover0.740.7720.4846
Pretty Stable
Sales General And Administrative To Revenue5.225.49124.1123
Slightly volatile
Research And Ddevelopement To Revenue24.4623.297714.4594
Slightly volatile
Capex To Revenue0.250.27340.3423
Very volatile
Cash Per Share10.711.26321.3215
Slightly volatile
Days Payables Outstanding883488227
Slightly volatile
Intangibles To Total Assets0.03260.03430.202
Slightly volatile
Current Ratio19.8618.914911.2637
Slightly volatile
Receivables Turnover17.6610.028626.5159
Slightly volatile
Debt To Equity0.00480.00510.0364
Slightly volatile
Capex Per Share0.02830.02981.0204
Slightly volatile
Average Receivables382.8 K375.3 K335.6 K
Slightly volatile
Revenue Per Share0.10.1090.9531
Slightly volatile
Interest Debt Per Share0.05630.05922.3318
Slightly volatile
Debt To Assets0.00460.00480.0278
Slightly volatile
Days Of Payables Outstanding883488227
Slightly volatile
Ebt Per Ebit0.740.80920.948
Slightly volatile
Long Term Debt To Capitalization0.05990.05090.054
Slightly volatile
Total Debt To Capitalization0.00480.00510.0327
Slightly volatile
Debt Equity Ratio0.00480.00510.0364
Slightly volatile
Quick Ratio19.8618.914911.301
Slightly volatile
Net Income Per E B T1.381.260.9553
Slightly volatile
Cash Ratio0.680.71792.1248
Slightly volatile
Days Of Sales Outstanding43.2636.39659.9252
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.01221.0368
Very volatile
Fixed Asset Turnover0.810.85150.9267
Pretty Stable
Debt Ratio0.00460.00480.0278
Slightly volatile
Price Sales Ratio243232238
Pretty Stable
Asset Turnover0.00840.00890.0304
Slightly volatile

Celldex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.4 B
Slightly volatile
Enterprise Value1.8 B1.7 B1.3 B
Slightly volatile

Celldex Fundamental Market Drivers

Cash And Short Term Investments725.3 M

Celldex Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.8 M10.3 M
Total RevenueM7.6 M
Cost Of Revenue3.2 MM
Stock Based Compensation To Revenue 4.88  4.63 
Sales General And Administrative To Revenue 5.49  5.22 
Research And Ddevelopement To Revenue 23.30  24.46 
Capex To Revenue 0.27  0.25 
Revenue Per Share 0.11  0.10 
Ebit Per Revenue(27.79)(26.40)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.